Oncolys Biopharma
4-1-28 Toranomon, Tokyo, Minato-ku, 105-0001, Japan
Overview
Oncolys BioPharma Inc. is a biopharmaceutical company. The Company operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The Company's main pipeline includes OBP-601 for the treatment of human immunodeficiency virus (HIV) infection; OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug; OBP-1101 (Telomescan F35), a virus for blood floating cancer cells (CTC) detection; OBP-401 (Telomescan), a virus for inflammatory disease detection, and OBP-1102, a virus for leukemia detection, among others.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Health Care
- Oncology
- Pharmaceutical
Investment portfolio
- Liquid Biotech
Led · Seed · Dec 2015
Liquid Biotech USA develops technology to identify and isolate individual circulating tumor cells (CTCs) from liquid biopsies for cancer diagnostics and gene discovery. The company is a spin-out from the Penn Center for Innovation at the University of Pennsylvania. Leadership includes Dr. Philip M. Sass (Chairman, President and CEO) and Jeffrey M. Janco (Executive Vice President and COO). In February 2015 it raised $2m in seed capital from Oncolys Biopharma. The company intends to use the funds to further develop its technology.
Team
No current team members are available.